

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007537 A3

(51) International Patent Classification⁷: C12N 15/86,
C07K 14/075, C12N 7/04, A61K 48/00

(FR). LEGRAND, Valérie [FR/FR]; 7, rue du Jet d'Eau,
F-67400 Illkirch Graffenstaden (FR).

(21) International Application Number:
PCT/IB2003/003336

(74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regim-
beau, 20, rue de Chazelles, F-75847 Paris Cedex 17. (FR).

(22) International Filing Date: 10 July 2003 (10.07.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02360204.8 10 July 2002 (10.07.2002) EP
60/409,228 10 September 2002 (10.09.2002) US

(71) Applicant (*for all designated States except US*): TRANS-
GENE S.A. [FR/FR]; 11, rue de Molsheim, F-67000 Stras-
bourg (FR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ROSA-CALA-
TRAVAL, Manuel [FR/FR]; 15, rue du Neufeld, F-67100
Strasbourg (FR). LEISSNER, Philippe [FR/FR]; 5D,
avenue du Général de Gaulle, F-69300 Caluire et Cuire


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

[Continued on next page]

(54) Title: MODIFIED ADENOVIRAL FIBER WITH ABLATED TO CELLULAR RECEPTORS



Competitor soluble Heparin (30 µg/ml)

(57) Abstract: The present invention concerns a modified adenoviral fiber containing at least one mutation affecting one or more amino acid residue(s) of said adenoviral fiber interacting with at least one glycosaminoglycan and/or sialic acid-containing cellular receptor, as well as a trimer of such a modified adenoviral fiber. The present invention also relates to a DNA fragment, an expression vector encoding said modified adenoviral fiber. The present invention also concerns an adenoviral particle lacking a wild-type fiber and comprising the trimer of modified adenoviral fibers as well as a process for producing such an adenoviral particle. The present invention also provides a composition comprising such an adenoviral particle and the therapeutic use thereof.

WO 2004/007537 A3